Welcome to our dedicated page for Accuray Incorp news (Ticker: ARAY), a resource for investors and traders seeking the latest updates and insights on Accuray Incorp stock.
Accuray Incorporated develops, sells, and supports radiation therapy systems used in cancer treatment and neuro-radiosurgery. Company news centers on product and service revenue, installation timing, gross margin factors, and non-GAAP operating measures, as well as updates tied to its CyberKnife and Radixact treatment platforms and the Accuray Stellar configuration.
Recurring developments also include commercial leadership changes, equity inducement awards, and strategic transformation actions involving organizational realignment, cost structure, outsourcing, engineering resources, and sales enablement. Accuray's updates frame the company as a medical technology issuer with capital equipment sales, service revenue, and global commercialization priorities.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Accuray Incorporated (NASDAQ: ARAY) reported strong financial results for Q3 fiscal 2023, ending March 31, 2023. Net revenue reached $118.1 million, a 22.8% increase year-over-year, while GAAP net income was $0.6 million, compared to a loss of $1.0 million in the prior year. Adjusted EBITDA surged to $8.3 million, up 53.5%. The company shipped a record 30 systems, marking a 67% growth from the previous year. However, gross product orders were $73.8 million, down from $88.6 million in the same quarter last year, and order backlog decreased by 12.7% to $506.6 million. Fiscal year guidance remains steady, with a focus on continued innovation and strategic partnerships.
Accuray Incorporated (NASDAQ: ARAY) will announce its third quarter fiscal 2023 financial results on April 26, 2023, following the quarter ending March 31, 2023. The company will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET. Interested parties can participate via dial-in or listen to a live webcast on the company's Investor Relations website.
Details for the conference call include dial-in numbers: 833-316-0563 (USA) and 412-317-5747 (international). A replay will be available shortly after the call, lasting for one week. Accuray is dedicated to advancing radiation therapy, aiming to enhance patient care.
Accuray Incorporated (NASDAQ: ARAY) will participate in the 33rd Annual Oppenheimer Healthcare Conference from March 13-15, 2023. The management team is scheduled for a fireside chat on March 14, 2023, at 1:00 PM PST / 4:00 PM EST. A live webcast will be available on the Accuray website, with a replay accessible for 90 days post-event. The Oppenheimer Conference aims to connect institutional investors with diverse healthcare companies across sectors. Accuray, headquartered in Sunnyvale, California, focuses on advancing radiation therapy to enhance patient outcomes.
Accuray Incorporated (NASDAQ: ARAY) will participate in the Cowen 43rd Annual Health Care Conference from March 6-8, 2023. The management team is scheduled for a Fireside Chat on March 6 at 10:30am PST (1:30pm EST). Interested parties can access a live webcast on the Accuray investor website, with a replay available afterward. Accuray is dedicated to advancing radiation therapy technologies to enhance patient care in oncology and neuro-radiosurgery. Based in Sunnyvale, California, the company focuses on innovative solutions to meet diverse patient needs.